Serum Concentrations of Fibroblast Growth Factor 19 in Patients With Obesity and Type 2 Diabetes Mellitus: the Influence of Acute Hyperinsulinemia, Very-Low Calorie Diet and PPAR-α Agonist Treatment

The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and...

Full description

Saved in:
Bibliographic Details
Published inPhysiological research Vol. 60; no. 4; pp. 627 - 636
Main Authors MRÁZ, M., LACINOVÁ, Z., KAVÁLKOVÁ, P., HALUZÍKOVÁ, D., TRACHTA, P., DRÁPALOVÁ, J., HANUŠOVÁ, V., HALUZÍK, M.
Format Journal Article
LanguageEnglish
Published Czech Republic 01.01.2011
Subjects
Acute Disease
Adult
Biomarkers - blood
Blood Glucose - metabolism
Caloric Restriction - methods
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - therapy
Female
Fenofibrate - pharmacology
Fenofibrate - therapeutic use
Fibroblast Growth Factors - blood
Humans
Hyperinsulinism - blood
Hyperinsulinism - therapy
Insulin Resistance
Middle Aged
Obesity - blood
PPAR alpha - agonists
PPAR alpha - physiology
Treatment Outcome
Online AccessGet full text
ISSN0862-8408
1802-9973
DOI10.33549/physiolres.932099

Cover

Abstract The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-α agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1±12.7 vs. 202.2±16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58±26.2 vs. 107.47±25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
AbstractList The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1+/-12.7 vs. 202.2+/-16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58+/-26.2 vs. 107.47+/-25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-α agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1±12.7 vs. 202.2±16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58±26.2 vs. 107.47±25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
Author KAVÁLKOVÁ, P.
HANUŠOVÁ, V.
TRACHTA, P.
DRÁPALOVÁ, J.
LACINOVÁ, Z.
MRÁZ, M.
HALUZÍKOVÁ, D.
HALUZÍK, M.
Author_xml – sequence: 1
  givenname: M.
  surname: MRÁZ
  fullname: MRÁZ, M.
– sequence: 2
  givenname: Z.
  surname: LACINOVÁ
  fullname: LACINOVÁ, Z.
– sequence: 3
  givenname: P.
  surname: KAVÁLKOVÁ
  fullname: KAVÁLKOVÁ, P.
– sequence: 4
  givenname: D.
  surname: HALUZÍKOVÁ
  fullname: HALUZÍKOVÁ, D.
– sequence: 5
  givenname: P.
  surname: TRACHTA
  fullname: TRACHTA, P.
– sequence: 6
  givenname: J.
  surname: DRÁPALOVÁ
  fullname: DRÁPALOVÁ, J.
– sequence: 7
  givenname: V.
  surname: HANUŠOVÁ
  fullname: HANUŠOVÁ, V.
– sequence: 8
  givenname: M.
  surname: HALUZÍK
  fullname: HALUZÍK, M.
  organization: Third Department of Medicine, General University Hospital and First Medical Faculty, Charles University, Prague, Czech Republic
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21574752$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAUhS1URKctL8AC3QcgrX8mccxuNGXaSoM6giksIye5YYwSe2Q7qvJYPAU7ngkz0wqJBau7uOc79-qcM3JinUVC3jB6KUQ-V1f73RSM6z2GSyU4VeoFmbGS8kwpKU7IjJYFz8o5LU_JWQjfKeWSSvGKnHKWy7nM-Yz8_Ix-HGDpbIM2eh2NswFcBytTe1f3OkS48e4x7mClm-g8MAXGwiYpExDgq0mr-xqDiRNo28J22iNwuDa6xogBPmLfmziG9xB3CHe260dMx_7cWDRjRLhNgDc2jL2xOBj9Dr6gn7K1e4Sl7p03mMwwHsw3m8Wn7NcPWHxz1qTXth51HNIjF-Rlp_uAr5_mOXlYfdgub7P1_c3dcrHOGjEvYsapaLtWcNlSxnOp87opVSmwLDvkORYN5rKohdIt11R1sqtzxrqiRsY4b3Mpzsnbo-9-rAdsq703g_ZT9ZxoEpRHQeNdCB67qjHxEGtK1_QVo9WhvOpvedWxvITyf9Bn9_9AvwH8YaTs
CitedBy_id crossref_primary_10_1210_er_2018_00134
crossref_primary_10_1172_jci_insight_174164
crossref_primary_10_3892_br_2017_890
crossref_primary_10_1097_QAI_0b013e318271c2c7
crossref_primary_10_1111_jcmm_17614
crossref_primary_10_1007_s11695_020_04807_7
crossref_primary_10_1210_jc_2013_3367
crossref_primary_10_1146_annurev_pharmtox_032322_093904
crossref_primary_10_3389_fendo_2020_568500
crossref_primary_10_1038_s41598_025_88013_4
crossref_primary_10_1111_jgh_16687
crossref_primary_10_2478_ahem_2022_0045
crossref_primary_10_1016_j_cca_2015_09_006
crossref_primary_10_1515_hmbci_2020_0075
crossref_primary_10_1161_ATVBAHA_118_311726
crossref_primary_10_1186_s12916_017_0797_5
crossref_primary_10_1210_en_2011_2145
crossref_primary_10_1016_j_numecd_2017_10_009
crossref_primary_10_1038_nrd_2015_9
crossref_primary_10_1111_obr_13038
crossref_primary_10_1371_journal_pone_0081190
crossref_primary_10_1038_s41392_024_01811_6
crossref_primary_10_4274_imj_galenos_2023_19626
crossref_primary_10_1016_j_clnu_2016_04_027
crossref_primary_10_1016_j_ajpath_2023_02_014
crossref_primary_10_33549_physiolres_932792
crossref_primary_10_1111_obr_13075
crossref_primary_10_1530_JOE_16_0206
crossref_primary_10_1152_ajpendo_00156_2024
crossref_primary_10_3389_fendo_2023_1169624
crossref_primary_10_1038_ijo_2015_2
crossref_primary_10_1016_j_cytogfr_2015_07_016
crossref_primary_10_1016_j_diabet_2024_101570
crossref_primary_10_1038_ijo_2014_76
crossref_primary_10_1038_s42255_019_0074_3
crossref_primary_10_1097_MPG_0000000000000774
crossref_primary_10_1177_2050640614527938
crossref_primary_10_1016_j_jhep_2021_07_029
crossref_primary_10_1517_13543784_2015_1006357
crossref_primary_10_3389_fendo_2021_805722
crossref_primary_10_1016_j_bpsgos_2024_100332
crossref_primary_10_1038_s41467_021_24914_y
crossref_primary_10_1186_s12967_016_0821_0
crossref_primary_10_3389_fendo_2021_799648
crossref_primary_10_3389_fphar_2022_916866
crossref_primary_10_1038_ncomms5573
crossref_primary_10_1007_s11892_017_0866_3
crossref_primary_10_1111_jdi_12859
crossref_primary_10_1016_j_ejphar_2023_176248
crossref_primary_10_2337_dc12_1766
crossref_primary_10_1016_j_clnu_2025_03_013
crossref_primary_10_1111_obr_13017
crossref_primary_10_1371_journal_pone_0072345
crossref_primary_10_1002_oby_20208
Cites_doi 10.1055/s-0029-1243249
10.1016/j.tig.2004.08.007
10.1016/j.cca.2010.08.003
10.1210/jcem.85.10.6898
10.1016/0026-0495(82)90231-1
10.1038/nm1501
10.1210/me.2002-0120
10.1007/bf00280883
10.1210/endo.143.5.8850
10.1056/nejm198005293022202
10.33549/physiolres.931371
10.1016/j.cmet.2005.09.001
10.1210/en.2003-1671
10.1073/pnas.0506982103
10.1111/j.1365-2796.2006.01731.x
10.1006/cyto.1999.0485
10.1172/jci25604
10.1002/hep.23831
10.1111/j.1365-2265.2006.02474.x
10.1074/jbc.m808747200
10.1074/jbc.m510258200
10.1081/erc-200034301
10.1074/jbc.m411771200
10.1074/jbc.275.20.15482
10.1101/gad.1083503
10.1097/01.smj.0000208120.73327.db
10.1016/s0167-4781(98)00255-3
10.1002/hep.22771
10.1152/physrev.00010.2008
10.33549/physiolres.931058
10.1152/ajpgi.00322.2009
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.33549/physiolres.932099
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1802-9973
EndPage 636
ExternalDocumentID 21574752
10_33549_physiolres_932099
Genre Research Support, Non-U.S. Gov't
Journal Article
Comparative Study
GroupedDBID ---
04C
123
29O
2WC
36B
53G
7RV
7X7
88E
8AO
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AAYXX
ABUWG
ACGFO
ACIHN
ACPRK
ADBBV
AEAQA
AENEX
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BKEYQ
BMSDO
BPHCQ
BVXVI
BYOGL
C1A
CCPQU
CITATION
DIK
DU5
DWQXO
E3Z
EBD
EIHBH
EMB
EMOBN
EN8
EOJEC
EX3
F5P
F8P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HMCUK
LK8
M1P
M2O
M7P
MK0
NAPCQ
OBODZ
OK1
OVT
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
RNS
RPM
SV3
TR2
U5U
UKHRP
UNMZH
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-c346t-203dfd327d01257a5bc8983e88fe25e6ce576b39ad2a09f7fb511f6be1122d573
ISSN 0862-8408
IngestDate Wed Jun 21 08:27:04 EDT 2023
Thu Apr 24 23:04:09 EDT 2025
Tue Jul 01 03:06:48 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c346t-203dfd327d01257a5bc8983e88fe25e6ce576b39ad2a09f7fb511f6be1122d573
OpenAccessLink https://doi.org/10.33549/physiolres.932099
PMID 21574752
PageCount 10
ParticipantIDs pubmed_primary_21574752
crossref_citationtrail_10_33549_physiolres_932099
crossref_primary_10_33549_physiolres_932099
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-01-01
PublicationDateYYYYMMDD 2011-01-01
PublicationDate_xml – month: 01
  year: 2011
  text: 2011-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Czech Republic
PublicationPlace_xml – name: Czech Republic
PublicationTitle Physiological research
PublicationTitleAlternate Physiol Res
PublicationYear 2011
References ref13
ref12
ref15
ref14
ref31
ref30
ref11
ref10
ref0
ref2
ref1
ref17
ref16
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref19
  doi: 10.1055/s-0029-1243249
– ident: ref12
  doi: 10.1016/j.tig.2004.08.007
– ident: ref25
  doi: 10.1016/j.cca.2010.08.003
– ident: ref26
  doi: 10.1210/jcem.85.10.6898
– ident: ref5
– ident: ref2
  doi: 10.1016/0026-0495(82)90231-1
– ident: ref9
  doi: 10.1038/nm1501
– ident: ref18
  doi: 10.1210/me.2002-0120
– ident: ref16
  doi: 10.1007/bf00280883
– ident: ref27
  doi: 10.1210/endo.143.5.8850
– ident: ref21
  doi: 10.1056/nejm198005293022202
– ident: ref7
  doi: 10.33549/physiolres.931371
– ident: ref10
  doi: 10.1016/j.cmet.2005.09.001
– ident: ref6
  doi: 10.1210/en.2003-1671
– ident: ref31
  doi: 10.1073/pnas.0506982103
– ident: ref14
  doi: 10.1111/j.1365-2796.2006.01731.x
– ident: ref28
  doi: 10.1006/cyto.1999.0485
– ident: ref15
  doi: 10.1172/jci25604
– ident: ref3
  doi: 10.1002/hep.23831
– ident: ref20
  doi: 10.1111/j.1365-2265.2006.02474.x
– ident: ref22
  doi: 10.1074/jbc.m808747200
– ident: ref4
  doi: 10.1074/jbc.m510258200
– ident: ref1
  doi: 10.1081/erc-200034301
– ident: ref29
  doi: 10.1074/jbc.m411771200
– ident: ref30
  doi: 10.1074/jbc.275.20.15482
– ident: ref8
  doi: 10.1101/gad.1083503
– ident: ref11
  doi: 10.1097/01.smj.0000208120.73327.db
– ident: ref17
  doi: 10.1016/s0167-4781(98)00255-3
– ident: ref23
  doi: 10.1002/hep.22771
– ident: ref13
  doi: 10.1152/physrev.00010.2008
– ident: ref0
  doi: 10.33549/physiolres.931058
– ident: ref24
  doi: 10.1152/ajpgi.00322.2009
SSID ssj0027073
Score 2.1913295
Snippet The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes...
SourceID pubmed
crossref
SourceType Index Database
Enrichment Source
StartPage 627
SubjectTerms Acute Disease
Adult
Biomarkers - blood
Blood Glucose - metabolism
Caloric Restriction - methods
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - therapy
Female
Fenofibrate - pharmacology
Fenofibrate - therapeutic use
Fibroblast Growth Factors - blood
Humans
Hyperinsulinism - blood
Hyperinsulinism - therapy
Insulin Resistance
Middle Aged
Obesity - blood
PPAR alpha - agonists
PPAR alpha - physiology
Treatment Outcome
Title Serum Concentrations of Fibroblast Growth Factor 19 in Patients With Obesity and Type 2 Diabetes Mellitus: the Influence of Acute Hyperinsulinemia, Very-Low Calorie Diet and PPAR-α Agonist Treatment
URI https://www.ncbi.nlm.nih.gov/pubmed/21574752
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6F9oUXBJSjHNU8UF6Cg8-1zZubQylNghWlVdWXyMe6IJEYFUdV-Ff8Ct74R0jMHt4cHKK8WJF3M7Y1n3dnxt_MEPKiyEI3yJzMsH3Gi2pn-EqlSW5QmqfUw1v3Ep6cPBzR_qn79tw7bzR-rLGWFlXayr78Nq_kf7SK51CvPEv2BprVQvEE_kb94hE1jMd_0jG-6IsZT9qTFEtNauuhD1ymaBdXPLZ0Xb1v9kRbHfT9eXwjlrVUOfUVh1RrAPEVYSIDsp06IDvk5Tqrxeea_XFctzQRBmzGOQb9Ja-VLBntbCapt2fsamkMymue-VWiL44CmWSyx3E0Ng7b3cMjqxldlrxsb3NSc93XDWXBTNULsypJpEPXwzH_wB9YFyKe29Ksoqh9PHp3JsfEZxc9dBKp04OT9QmxntCPBqcXYqCzMaPTWg-MiPTAOjCi1k-Ki71ryuWdyfU9wA0gDH1nbc2msjiB2v6prMeyvbM4DjrSvB-yfHp87BZavqZs7rRZxntre9WkR3S3hJTpSsZUyrhFdm3f5yyD3aPuKB6vIgampEjUTyKzvoSU17_cyYZlteEjCVtpcpfcUU4ORBKx90iDze-TvWieVOVsCS9BK3e5R74JEMMmiKEsYAVikCAGCWKwQvgwhxrEwEEMCsSAGAMOYrChBjHUIH4DCGHQEObXEBCGbQi_ghrAoAAMHMBCuADw96-gwAsavA_Iaa87afcN1V3EyByXVriQOHmRO7afo43m-YmXZkEYOCwICmZ7jGYMXfHUCZPcTsyw8IsUfZOCpgw9FDv3fOch2ZmXc_aYADr9OXPMxMo95rpJllBeRMv0CppYReBm-8SqNTPNVOl93gHm4_TPmNgnTf2fT7LwzF9nP5IK13PRlPdd37Of3EjOU3J79So9IzvV1YI9R6u7Sg8UNg9E1AqPo3j4E9_f2_E
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Concentrations+of+Fibroblast+Growth+Factor+19+in+Patients+With+Obesity+and+Type+2+Diabetes+Mellitus%3A+the+Influence+of+Acute+Hyperinsulinemia%2C+Very-Low+Calorie+Diet+and+PPAR-%CE%B1+Agonist+Treatment&rft.jtitle=Physiological+research&rft.au=MR%C3%81Z%2C+M.&rft.au=LACINOV%C3%81%2C+Z.&rft.au=KAV%C3%81LKOV%C3%81%2C+P.&rft.au=HALUZ%C3%8DKOV%C3%81%2C+D.&rft.date=2011-01-01&rft.issn=0862-8408&rft.eissn=1802-9973&rft.spage=627&rft.epage=636&rft_id=info:doi/10.33549%2Fphysiolres.932099&rft.externalDBID=n%2Fa&rft.externalDocID=10_33549_physiolres_932099
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0862-8408&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0862-8408&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0862-8408&client=summon